Population pharmacokinetic model pins tirzepatide's half-life at 5.4 days

A population pharmacokinetic study published February 14, 2024, in CPT: Pharmacometrics & Systems Pharmacology reports that tirzepatide, the active ingredient in Mounjaro and Zepbound, has a mean half-life of about 5.4 days ^[1]. The paper, by Eli Lilly researchers Karen Schneck and Shweta Urva, pooled data from 19 studies to build a two-compartment model describing how the drug moves through and clears from the body ^[1].

Half-life is the time it takes for half of a drug to leave the bloodstream. A half-life of roughly 5.4 days helps explain why tirzepatide is dosed once a week: the drug stays active in the body long enough that weekly injections keep levels fairly steady between doses ^[1]. The model also estimated an apparent clearance rate of 0.061 liters per hour, a measure of how quickly the body removes the drug from circulation, and found that repeated weekly dosing leads to roughly 1.7-fold accumulation of the drug in the body compared with a single dose ^[1].

The same simulations underpin the four-day missed-dose guidance found on tirzepatide's label. Because the drug clears slowly, the model supports the idea that if a weekly dose is missed, taking it within four days of the missed time still fits within the expected pharmacokinetic profile, according to the paper ^[1]. Beyond half-life, the analysis is described as a "cohesive understanding of tirzepatide PKs" meant to support dosing guidance for prescribers, and the authors report that no dose adjustments were found necessary based on renal impairment, hepatic impairment, body weight, sex, age, race, or ethnicity ^[1].

The data behind the model came from a wide range of trials: phase I studies in healthy volunteers and people with type 2 diabetes, studies in people with kidney or liver impairment, bioavailability and injection-site studies, and phase II and III trials including the SURPASS program conducted in the United States, Japan, and other countries ^[1]. Doses studied ranged from as low as 0.25 mg to the approved maximum of 15 mg once weekly, and PK sampling continued for up to 109 weeks of continuous treatment in some studies ^[1]. The paper also notes that tirzepatide's average absolute bioavailability, meaning the fraction of an injected dose that actually reaches the bloodstream, is about 80% based on intravenous comparison data ^[1].

Why it matters for patients

This kind of pharmacokinetic modeling does not change how tirzepatide is prescribed, but it explains the reasoning behind existing label instructions that patients on Mounjaro or Zepbound may already follow, such as the guidance on how soon a missed weekly dose can be taken ^[1]. Because the drug clears slowly from the body, over roughly five days for each halving of the amount present, effects from a dose, both intended and unintended, may persist for more than a week after an injection ^[1].

The finding that no dose adjustments were needed across different ages, sexes, races, ethnicities, body weights, and kidney or liver function may be reassuring for patients wondering whether their individual characteristics affect how the drug works in their body, according to the study's authors ^[1]. However, the source cited here is a pharmacokinetic modeling paper, not a clinical outcomes study, so it does not address efficacy or side effects directly; those are covered in the separate SURPASS trials referenced within the paper ^[1].

What happens next

The paper states that the tirzepatide population PK model can be used to predict drug exposure for various scenarios or populations going forward, which may support future labeling or research questions, though no specific dated milestones for further label changes are given in this source ^[1].